Download PDF: Complete Report
Patients with viral respiratory infections often benefit from the administration of aerosolized medications by nebulizer. However, it is uncertain if receipt of nebulized medications increases droplet or aerosol production with associated transmission of viruses such as SARS-CoV-2. Health care systems and providers have an urgent need to understand the risk of viral transmission during nebulizer treatments for patients presenting with presumed or confirmed cases of COVID-19. To that end, we conducted this ultra-rapid review to address the following key question: What is the risk of transmitting SARS-CoV-2, SARS, MERS, and influenza with administration of drugs via nebulizer?
What is the risk of transmitting SARS-CoV-2, SARS, MERS, and influenza with administration of drugs via nebulizer?
Goldstein K, Ghadimi K, Mystakelis H, et al. Risk of Transmitting Coronavirus Disease 2019 During Nebulizer Treatment: A Systematic Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery. Published online April 21, 2021. doi: https://doi.org/10.1089/jamp.2020.1659.